Key result
Safflower yellow slows weight gain and improves hepatic steatosis and glucose metabolism in obese mice.
Why the study?
The gastrointestinal tract and liver mediate the anti-obesity effects of intragastric safflower yellow, but its effect on MAFLD and possible mechanisms remained to be investigated.
Does intragastric safflower yellow alleviate metabolic dysfunction-associated fatty liver disease in diet-induced obesity mice?
Does intragastric safflower yellow alleviate metabolic dysfunction-associated fatty liver disease in diet-induced obesity mice?
Intragastric safflower yellow alleviates metabolic dysfunction-associated fatty liver disease in mice, likely by modulating gut microbiota and improving liver endoplasmic reticulum stress.
Answers are grounded in this paper and cite their sources.
Intragastric SY attenuates MAFLD in DIO mice; leaves open translation to human therapy.
The gut microbiota was reported to play a significant role in the progression of the metabolic associated fatty liver disease (MAFLD). Our recent study suggested that gastrointestinal tract and liver were important targets mediating the anti-obesity effects of intragastric safflower yellow (SY). Therefore, our present study aims to investigate the effect of intragastric SY on MAFLD and possible mechanism. DIO mice were treated with 125 mg/kg/d SY for 12 weeks by gavage. We found intragastric SY significantly slowed weight gain of body, reduced the food intake and liver weight, improved hepatic steatosis, liver function and glucose metabolism in DIO mice. The comparison between OGTT and IPGTT illustrated OGTT produced a better improvement of glucose tolerance after SY treatment. We also found intragastric SY significantly increased the energy expenditure and locomotor activity of DIO mice. SY obviously decreased the expression of lipogenesis-associated and ERS-related genes in liver of DIO mice and PA-induced MAFLD hepatocyte model. Gut microbiota analysis demonstrated intragastric SY apparently changed the diversity and composition of gut microbiota of DIO mice. Further function prediction analysis indicated that gut microbiotas in SY-treated mice was positively related with energy metabolism, lipid metabolism and endocrine system. Intragastric SY has a significant therapeutic effect on MAFLD, which is mediated partly by modulating gut microbiota and improving liver ERS.
No takes yet. Share an insight, caveat, or question.
Hu et al. (2023) studied Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD). Intragastric safflower yellow (SY) was evaluated on Weight gain, hepatic steatosis, liver function, and glucose metabolism. Intragastric safflower yellow significantly slowed weight gain, improved hepatic steatosis and glucose metabolism, and modulated gut microbiota in diet-induced obesity mice.
Synapse has enriched 10 related papers. Consider them for comparative context: